Serotonin 5-HT2B receptor agonism and valvular heart disease : implications for the development of psilocybin and related agents
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - 22(2023), 10 vom: 23. Juli, Seite 881-883 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McIntyre, Roger S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2RV7212BP0 |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 23.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14740338.2023.2248883 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360807607 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360807607 | ||
| 003 | DE-627 | ||
| 005 | 20240123231854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14740338.2023.2248883 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM360807607 | ||
| 035 | |a (NLM)37581427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McIntyre, Roger S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serotonin 5-HT2B receptor agonism and valvular heart disease |b implications for the development of psilocybin and related agents |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a 5HT2B receptor agonism | |
| 650 | 4 | |a FDA guidance | |
| 650 | 4 | |a Lysergic acid diethylamide (LSD) | |
| 650 | 4 | |a Psilocybin | |
| 650 | 4 | |a ecstasy | |
| 650 | 4 | |a valvular heart disease | |
| 650 | 7 | |a Psilocybin |2 NLM | |
| 650 | 7 | |a 2RV7212BP0 |2 NLM | |
| 650 | 7 | |a Serotonin |2 NLM | |
| 650 | 7 | |a 333DO1RDJY |2 NLM | |
| 650 | 7 | |a Lysergic Acid Diethylamide |2 NLM | |
| 650 | 7 | |a 8NA5SWF92O |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d 2002 |g 22(2023), 10 vom: 23. Juli, Seite 881-883 |w (DE-627)NLM126588422 |x 1744-764X |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:10 |g day:23 |g month:07 |g pages:881-883 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14740338.2023.2248883 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 10 |b 23 |c 07 |h 881-883 | ||